Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

ClinicalTrials.gov ID: NCT06014658

Public ClinicalTrials.gov record NCT06014658. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 5, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Open-label, Phase 1/1b / Phase 2 Dose Finding, Safety, and Pharmacokinetic Study of MBRC-101, an Anti-EphA5 Monomethyl Auristatin E (MMAE) Antibody Drug Conjugate, in Advanced Refractory Solid Tumors

Study identification

NCT ID: NCT06014658
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: MBrace Therapeutics; Industry
Enrollment: 130 participants

Conditions and interventions

Conditions

Cancer

Interventions

Antibody-Drug Conjugate Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 6, 2023
Primary completion: Jun 30, 2026
Completion: Oct 31, 2026
Last update posted: Mar 1, 2026

2023 – 2026

United States locations

U.S. sites: 17
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
UCSF Helen Diller Family Comprehensive Cancer Center	San Francisco	California	94158	Recruiting
University of Colorado, Anschutz Cancer Pavilion (ACP(	Aurora	Colorado	80045	Recruiting
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	Recruiting
University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Horizon Oncology Research	Lafayette	Indiana	47905	Completed
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Comprehensive Cancer Center of Nevada	Las Vegas	Nevada	89169	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	Recruiting
Columbia University Irving Medical Center	New York	New York	10032	Recruiting
Carolina BioOncology Institute	Huntersville	North Carolina	28078	Active, not recruiting
University of Pennsylvania, Abramson Cancer Center	Philadelphia	Pennsylvania	19014	Recruiting
Fox Chase Cancer Center	Philadelphia	Pennsylvania	19111	Recruiting
Medical University of South Carolina (MUSC)	Charleston	South Carolina	29425	Recruiting
PRISMA Health, Institute for Translational Oncology	Greenville	South Carolina	29605	Recruiting
NEXT Oncology	Austin	Texas	78758	Recruiting
NEXT Oncology	Irving	Texas	75039	Recruiting
NEXT Oncology	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06014658, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 1, 2026 · Synced May 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06014658 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →